🚀 VC round data is live in beta, check it out!
Context Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Context Therapeutics and similar public comparables like Alector, Medeze Group, Surrozen, Nuvectis Pharma and more.
Context Therapeutics Overview
About Context Therapeutics
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Founded
2015
HQ
Employees
12
Website
Financials (LTM)
EV
$162M
Context Therapeutics Financials
Context Therapeutics reported last 12-month revenue of —.
In the same LTM period, Context Therapeutics generated — in gross profit and had net loss of ($34M).
Revenue (LTM)
Context Therapeutics P&L
In the most recent fiscal year, Context Therapeutics reported revenue of — and EBITDA of ($30M).
Context Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($30M) | XXX | XXX | XXX |
| Net Profit | ($34M) | XXX | ($27M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Context Therapeutics Stock Performance
Context Therapeutics has current market cap of $238M, and enterprise value of $162M.
Market Cap Evolution
Context Therapeutics' stock price is $2.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $162M | $238M | 0.0% | XXX | XXX | XXX | $-0.29 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialContext Therapeutics Valuation Multiples
Context Therapeutics trades at (5.4x) EV/EBITDA.
Context Therapeutics Financial Valuation Multiples
As of March 17, 2026, Context Therapeutics has market cap of $238M and EV of $162M.
Equity research analysts estimate Context Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Context Therapeutics has a P/E ratio of (7.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $238M | XXX | $238M | XXX | XXX | XXX |
| EV (current) | $162M | XXX | $162M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (5.4x) | XXX | XXX | XXX |
| EV/EBIT | (4.3x) | XXX | (5.4x) | XXX | XXX | XXX |
| P/E | (7.0x) | XXX | (8.9x) | XXX | XXX | XXX |
| EV/FCF | (8.0x) | XXX | (5.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Context Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Context Therapeutics Margins & Growth Rates
Context Therapeutics' revenue in the last fiscal year grew by —.
Context Therapeutics' revenue per employee in the last FY averaged $0.0M.
Context Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 19% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Context Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Alector | XXX | XXX | XXX | XXX | XXX | XXX |
| Medeze Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Surrozen | XXX | XXX | XXX | XXX | XXX | XXX |
| Nuvectis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Reig Jofré | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Context Therapeutics M&A Activity
Context Therapeutics acquired XXX companies to date.
Last acquisition by Context Therapeutics was on XXXXXXXX, XXXXX. Context Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Context Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialContext Therapeutics Investment Activity
Context Therapeutics invested in XXX companies to date.
Context Therapeutics made its latest investment on XXXXXXXX, XXXXX. Context Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Context Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Context Therapeutics
| When was Context Therapeutics founded? | Context Therapeutics was founded in 2015. |
| Where is Context Therapeutics headquartered? | Context Therapeutics is headquartered in United States. |
| How many employees does Context Therapeutics have? | As of today, Context Therapeutics has over 12 employees. |
| Who is the CEO of Context Therapeutics? | Context Therapeutics' CEO is Martin A. Lehr. |
| Is Context Therapeutics publicly listed? | Yes, Context Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Context Therapeutics? | Context Therapeutics trades under CNTX ticker. |
| When did Context Therapeutics go public? | Context Therapeutics went public in 2021. |
| Who are competitors of Context Therapeutics? | Context Therapeutics main competitors are Alector, Medeze Group, Surrozen, Nuvectis Pharma. |
| What is the current market cap of Context Therapeutics? | Context Therapeutics' current market cap is $238M. |
| Is Context Therapeutics profitable? | No, Context Therapeutics is not profitable. |
| What is the current net income of Context Therapeutics? | Context Therapeutics' last 12 months net income is ($34M). |
| What is the current FCF of Context Therapeutics? | Context Therapeutics' last 12 months FCF is ($20M). |
| What is the current EV/FCF multiple of Context Therapeutics? | Current FCF multiple of Context Therapeutics is (8.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.